

inhibitors (TKI). TKI discontinuation in chronic phase CML is being implemented in the clinical routine. To investigate the outcome of the patients with chronic myeloid leukemia (CML) discontinued tyrosine kinase inhibitors (TKI) therapy **Case report:** TKI was prospectively discontinued in patients who were diagnosed with CML in the chronic phase treated with TKI for ≥ 5 years, and sustained molecular response 4.5 (MR4.5) for ≥ 2 years. Molecular relapse was defined as a single loss of major molecular response (MMR) (BCR-ABL1^{IS} >0.1%). **Methodology:** Standard qRT-PCR techniques were performed to evaluate minimal residual disease (MRD) **Results:** Twenty-one patients with chronic-phase CML were enrolled. The median duration of TKI treatment before discontinuation was 117 months (49-177) months. The median follow-up time after TKI discontinuation was 20 months (range: 1-117 months). The estimated TFR rate was 62% and 47.6% at 12 and 24 months after discontinuation respectively. Five patients experienced loss of MMR within 7 months after TKI discontinuation. All relapsed patients promptly resumed TKI therapy and regained at least major molecular response. **Conclusion:** Our data on the Tunisian population may provide a basis for the safety and feasibility of TKI discontinuation particularly in CML patients who are in sustained deep molecular response with longer TKI treatment duration.

<https://doi.org/10.1016/j.htct.2023.09.057>

Adult Hematology Abstract Categories

Coagulation Diseases

PP 08

AZERBAIJAN EXPERIENCE OF HAEMOPHILIA CARE

Gunel Alizada¹, Mehpara Kazımova², Elmira Gadımova¹, Hikmet Ibrahimlı²

¹ *Azerbaijan State Advanced Training Institute for Doctors named after Aziz Aliyev, Department of Haematology*

² *The State Agency on Mandatory Health Insurance*

Objective: As the management of haemophilia is complex, it is essential that those with the disorder should have ready access to a range of services provided by a multidisciplinary team of specialists. There is a State Program aimed at solving this problem in Azerbaijan. The purpose of the study to learn complex epidemiological characteristics which are necessary for justification of strategy on treatment and prevention of haemophilia. **Methodology:** For planning of prophylactic treatment in Baku city, there was obtained the database of all patients (by sex, age, diagnosis, severity) registered in the city (625 persons). The main group consisting of 52 patients with severe and 40 patients with moderate haemophilia-A was formed. Different variant treatment of 162 patients was organized in HTC: chemical synovectomy with rifampicin (44); phonophoresis with refined naftalan oil (44); phonophoresis with hydrocortisone (28); electrophoresis with KJ (35). **Results:** 77.9% of patients observed in treatment and prophylaxis

facilities in Baku were men, 59% were diagnosed with haemophilia A, 18.8% with severe and 31.5% with moderate haemophilia. Prophylactic treatment reduces the average annual number of bleeding episodes by 2.2 times in severe haemophilia and 2.1 times in moderate haemophilia. The model of prophylactic treatment of hemophilia can be applied in the infusion model 2 or 3 times a week as far as possible. **Conclusion:** The role of physiotherapeutic methods of hemarthrosis treatment was assessed and positive results were obtained. Due to the prevalence of polymorbidity in patients with hemophilia the complexity of their observation and treatment and the participation of specialists from several specialties is necessary. As the duration of haemophilia is proportional to the frequency of its complications, starting the prophylactic treatment at the stage when patients are first diagnosed is recommended.

<https://doi.org/10.1016/j.htct.2023.09.058>

PP 09

CHARACTERIZATION AND MANAGEMENT OF PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY: A RETROSPECTIVE SINGLE CENTER EXPERIENCE

Nigar Abdullayeva¹, Fahri Sahin¹, Zuhail Demirci¹, Bahar Sevgili¹

¹ *Ege University Medical Faculty Hospital Adult Hemophilia and Thrombosis Center, Izmir, Turkey*

Objective: Factor X deficiency (FXd) is a rare coagulation disorder that can be either hereditary or acquired. **Case report:** We characterized patients with FXd and evaluated their bleeding patterns and treatment strategies. **Methodology:** This retrospective review includes patients with FXd managed at Ege University Medical Faculty Hospital Ege Adult Hemophilia and Thrombosis Center. We analyzed demographic characteristics, laboratory results, bleeding scores, and treatments of five patients with FXd (Table). Patient 1 was admitted for further evaluation of menometrorrhagia and prolonged postpartum bleeding. She required treatment following birth, tooth extraction, and fractional curettage during follow-up. Coagulation tests were run as a part of in vitro fertilization in patient 2 and were abnormal. Family history was significant for a history of thrombosis in her mother. Blood tests were positive for Prothrombin 20210 G/A heterozygous mutation and lupus anticoagulants. The patient has never had any bleeding episodes in the follow-up. Patient 3 has a history of menometrorrhagia, gingival bleeding, and prolonged bleeding after an abortion. The sister of the patient has FXd. In follow-up, she was treated for subcutaneous hematoma, gingival, and post-cesarean bleeding. Patient 4 presented for evaluation of menometrorrhagia. She was treated for polypectomy, two cesarean sections, tooth extraction, intermittent recurrent ecchymosis, and epistaxis. Patient 5 was diagnosed at age one and was referred to us for further management of his condition. His initial presentation was consistent with subdural hematoma. In the follow-up, he was treated for

epistaxis, hematuria, subcutaneous hematoma, and gastrointestinal and gingival bleeding. He continues to take Factor X concentrate prophylactically. All the patients are currently healthy and regularly follow up in our center. **Results Conclusion:** Since there is no FX concentrate in our country yet, FFP is used. Patients should be treated with the appropriate FX preparation and a prophylactic approach should be applied in necessary patients.

Table. Patient Characteristics and Diagnostic Laboratory Results

Patient No	Age at analysis	Gender	FX %	PT sec 10.9-14.7	PTT sec 22.5-31.3	Bleeding score*	Treatment
1.	41	F	0.2	60.4	64.1	11	FFP, ES, PCC
2.	25	F	12.3	31.5	57.9	0	Not need
3.	18	F	0.8	37	19.3	11	FFP, ES, PCC
4.	34	F	34.4	13.9	28.3	15	FFP
5.	1	M	1	180	138	10	FFP, FXC, PCC

*- International Society for Thrombosis and Hemostasis/Scientific and Standardization Committee Bleeding Assessment Tool (ISTH-BAT), FFP- fresh frozen plasma, ES- erythrocyte suspension, PCC- prothrombin complex concentrate, FXC- Factor X concentrate, F- female, M-Male

<https://doi.org/10.1016/j.htct.2023.09.059>

Adult Hematology Abstract Categories

Lymphoma

PP 10

REACTION OF THE CIRCULATING REGULATORY T CELLS AFTER CHEMORADIATION THERAPY OF HODGKIN LYMPHOMA

Tatiana Mushkarina¹, Evgenija Kuzmina¹, Tatiana Bogatyreva¹, Ludmila Gritsova¹

¹ A. Tsyb Medical Radiological Research Centre MRRC

Objective: Purpose of the research is to determine the reaction of regulatory T cells after chemoradiation therapy of Hodgkin lymphoma. **Methodology:** 29 samples of peripheral blood of patients with Hodgkin lymphoma (before treatment – 10; after chemotherapy – 9; after consolidation radiotherapy – 10). Chemotherapy was carried out according to the following schemes: ABVD, BEACOPP with the addition of 1-2 courses of CVPP or COPP. The subsequent consolidation of radiation therapy was accomplished to a dose of 20-24 Gy. Treg-cells were identified by phenotype CD45+CD4+CD25+CD127-. Control group consisted of 40 practically healthy people. The group data were compared using the Mann-Whitney U test. **Results:** At the onset of Hodgkin lymphoma the percentage and absolute count of regulatory T cells corresponded to normal values (5.19%/0.036*10⁹ cells/l - Hodgkin lymphoma vs 3.69%/0.031*10⁹ cells/l - control level, p>0.05). After chemotherapy the percentage of regulatory T cells increased to 9.09%, p<0.05; the absolute count remained at the same level (0.037*10⁹ cells/l, p>0.05). After consolidation of radiation therapy the percentage of regulatory T cells was determined

at the level of 9.19%, p>0.05. The decrease of absolute count of regulatory T cells was statistically significant difference and was near 0.019*10⁹ cells/l. **Conclusion:** There is a relative redistribution of cells within a subpopulation of activated CD4+CD25+T cells towards an increase in the level of regulatory T cells after chemotherapy of Hodgkin lymphoma. The subsequent radiotherapy consolidation at a dose of 20-24 Gy continued to increase the sensitivity of regulatory T cells to the radiation component of chemoradiation therapy.

<https://doi.org/10.1016/j.htct.2023.09.060>

PP 11

CUTANEOUS RICHTER TRANSFORMATION IN THE 16TH YEAR OF FOLLICULAR LYMPHOMA DIAGNOSIS

Ulviyya Hasanzade¹, Yunus Catma¹, Nur Seda İbılı Cetinkaya¹, Beyza Oluk¹, Simge Erdem¹, Cem Hacıhaloğlu¹, Ahmet Oguz Celik², Musa Falay², Sevgi Kalayoglu Besisik¹

¹ Istanbul University İstanbul Medical Faculty, Department Of Internal Medicine Division Of Hematology

² İstanbul University İstanbul Medical Faculty, Department Of Internal Medicine

Case report: Richter transformation may develop in lymph nodes or rarely extranodally. A 70-year-old male with an exhausted appearance had a large malodorous wound progressing to necrosis on the left chest wall. He received two treatment lines 5 years apart for follicular lymphoma and was in remission. Histological evaluation showed triple hit diffuse large B cell lymphoma. PET-CT showed localized cutaneous and lymph node involvement. Two treatment lines did not control the disease. He passed on progression.

<https://doi.org/10.1016/j.htct.2023.09.061>

PP 12

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR HODGKIN LYMPHOMA, REAL WORLD EXPERIENCE OF A SINGLE CENTER EXPERIENCE

Carmino De Souza¹, Marcos Colella¹, Eliana Miranda¹, Lorena Bedotti¹, Afonso Vigorito^{1,2}

¹ University of Campinas - UNICAMP, Hematology and Hemotherapy Center

² University of Campinas - UNICAMP, Bone Marrow Transplantation Unit, Hematology and Hemotherapy Center

Objective: Hodgkin's Lymphoma (HL) during the years became a high curable hematology malignant disease.